Tamtam Try Tamtam free
Altria logo

Altria account plan

Leading tobacco product manufacturer

At a glance

Altria makes and sells US nicotine products, including Marlboro cigarettes, Copenhagen, on! pouches and NJOY e-vapor; FY2025 net revenues $23,279 million.

Altria Group, Inc., based in Richmond, Virginia, is a holding company whose operating companies make and sell nicotine products almost entirely in the United States: Philip Morris USA (cigarettes, including Marlboro), John Middleton (Black & Mild cigars), U.S. Smokeless Tobacco Company (Copenhagen and Skoal), Helix Innovations (on! nicotine pouches) and NJOY (e-vapor). Products go mainly to wholesalers and large retailers; one customer accounted for about 23% and another for about 19% of 2025 net revenues. In FY2025 net revenues were $23,279 million (-3.1%), reported net earnings $6,947 million and adjusted diluted EPS $5.42. Altria employed about 5,900 people at December 31, 2025 and holds equity stakes in ABI and Cronos.

Business units

Strategic priorities

2028 Enterprise Goals
Mid-single digits adjusted diluted EPS CAGR from a $4.87 base in 2022, progressive dividend growth in mid-single digits through 2028, debt-to-Consolidated EBITDA of about 2.0x and total adjusted OCI margin of at least 60% each year.
Grow on! in nicotine pouches
Pouches reached 61.2% of the oral category in Q3 2026; on! PLUS 12 mg went national with new flavours, backed by a retail trade program in stores representing approximately 90% of its volume.
Defend Marlboro's premium position
A data-driven, total portfolio approach uses Marlboro Cowboy Cut for value-sensitive smokers and Basic in discount; Marlboro held 60.0% of premium in Q3 2026.
Optimize & Accelerate
Centralising work, outsourcing transactional activities and automating processes for cumulative savings of at least $600 million by end-2029, reinvested in the business.
Growth beyond the US and beyond nicotine
Compete in top international innovative oral markets, develop heated tobacco and e-vapor abroad, and broadly distribute at least five non-nicotine products by 2028.

Latest results

In Q3 2026 net revenues rose 1.0% to $6,132 million and adjusted diluted EPS 4.8% to $1.52. Over nine months net revenues were $17,671 million (+1.4%) and adjusted diluted EPS $4.33 (+5.1%), with higher pricing and duty refunds on contract-manufactured export cigarettes offsetting lower volume and mix toward discount. Domestic cigarette volume fell 2.8% over nine months. Full-year 2026 adjusted diluted EPS guidance was raised to $5.66 to $5.74, growth of 4.5% to 6.0% from $5.42 in 2025.

Investments and deals

USSTC Facilities Consolidation
Announced May 2026: Nashville, Tennessee manufacturing moves to a new plant on the Hopkinsville, Kentucky campus, substantially complete in Q1 2028, for about $180 million of pre-tax charges.
Capital expenditure
2025 capex rose 52.1% to $216 million for manufacturing capabilities and innovative products; 2026 capex is expected at $300 million to $375 million.
Contract manufacturing
Contract-manufactured export cigarettes reached 2,941 million sticks over nine months of 2026 versus 786 million; 2026 guidance includes investments in contract manufacturing capabilities.
Shareholder returns
Dividend raised 4.7% to $1.11 per quarter in August 2026; buybacks of $735 million over nine months and a $1 billion program expansion expiring December 31, 2027.

Challenges and risks

Cigarette volume decline and trade-down
Inflation-squeezed adult consumers move to discount; industry discount share reached 34.1% in Q3 2026 and Marlboro's total share fell 1.0 point.
Illicit e-vapor
Illicit flavored disposables are estimated at about 70% of the e-vapor category, and Altria says enforcement is insufficient.
NJOY patent litigation
The ITC exclusion order keeps NJOY ACE off the market, and guidance assumes it does not return in 2026.
MST decline and pouch competition
Copenhagen and Skoal shipments fell 10.5% and 12.5% over nine months of 2026, while competitive investment in pouches remained elevated.
FDA regulation
PMTA outcomes, a proposed maximum-nicotine standard and state flavour bans weigh on the portfolio; Helix and NJOY sued the FDA over authorization timelines.

What leadership says

“Altria delivered strong financial performance in the third quarter, growing adjusted diluted earnings per share by 4.8%, while continuing to invest in our Vision and building on our foundation for the future.”

Sal Mancuso, Chief Executive Officer · Q3 2026 earnings release, October 29, 2026

“Sustained progress on harm reduction requires a more durable foundation, an efficient and predictable authorization process established through rulemaking.”

Sal Mancuso, Chief Executive Officer · Q3 2026 earnings call, October 29, 2026

“We have not announced when we're going back in the market, but we do plan on being back in the evapor market”

Sal Mancuso, Chief Executive Officer · Q3 2026 earnings call, October 29, 2026

“For harm reduction to succeed, 2 things are necessary, a more efficient authorization process and consistent enforcement over time.”

Sal Mancuso, Chief Executive Officer · Q2 2026 earnings call, July 30, 2026

Where a supplier can help

Process automation and outsourcing
Optimize & Accelerate's outsourcing of transactional activities and automation, with at least $600 million of targeted savings, opens doors for automation and business-process service providers.
Manufacturing and plant build-out
The USSTC move to Hopkinsville and higher 2026 capex for manufacturing and contract manufacturing favour equipment, engineering and construction suppliers.
Retail execution and trade marketing
Growing on! PLUS through retail trade programs, events and paid social, and the data-driven Marlboro portfolio approach, call for retail analytics and trade marketing tools.
Regulatory and compliance support
PMTA filings, FDA rulemaking and planned e-vapor re-entry create demand for regulatory science, testing and compliance services.

Tamtam's reading of the priorities and challenges above, not the company's own words.

Selling to companies like Altria?

Tamtam finds the companies that match your ideal customer, researches each account and tells you who to contact and when.

Find similar companies

Key documents

Read in full by Tamtam; each summary links to the document itself.

Questions about Altria

What does Altria do?

Altria's operating companies make and sell nicotine products in the United States: Marlboro cigarettes, Black & Mild cigars, Copenhagen and Skoal smokeless tobacco, on! nicotine pouches and NJOY e-vapor.

What is Altria's revenue?

FY2025 net revenues were $23,279 million, down 3.1%. Over the first nine months of 2026 net revenues were $17,671 million, up 1.4%.

How many employees does Altria have?

About 5,900 people at December 31, 2025, 26% of them hourly unionised manufacturing employees.

Who leads Altria?

Sal Mancuso became CEO after the May 14, 2026 annual meeting, succeeding William F. Gifford, Jr.; Heather Newman is CFO.

What is Altria's strategy?

Its Vision, Moving Beyond Smoking, aims to transition adult smokers to smoke-free products such as on! and NJOY while keeping leadership in US tobacco and meeting its 2028 Enterprise Goals.

Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)